Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients’ lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Kymera Therapeutics, Inc. (KYMR) reported revenue of $65M in Q2 2026 (quarter ended June 30, 2026), up 466% from the same quarter a year earlier. That came with a gross margin of 0.0% and net loss of $61M. For the full year FY2025, revenue was $39M (−17% year on year) and net income −$311M.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.